Abstract
Results of previous studies suggest that N-desmethyladinazolam, the major metabolite of adinazolam in man, contributes substantially to psychomotor effects and sedation observed following adinazolam administration. Therefore, the pharmacokinetics and pharmacodynamics of N-desmethyladinazolam were explored following administration of single oral doses of placebo and solutions containing 10, 30, and 50 mg N-desmethyladinazolam mesylate in a double-blind, randomized, four-way crossover design to 15 healthy male volunteers. Plasma concentrations of N-desmethyladinazolam were determined by HPLC. Psychomotor performance tests (digit symbol substitution and card sorting by fours and suits), memory tests and sedation scoring were also performed following drug administration. N-desmethyladinazolam pharmacokinetics were dose independent over this range. Doserelated performance effects were observed at 1, 2, and 6 h after dosing. Memory was likewise affected at 2 h. Psychomotor performance decrements correlated with log N-desmethyladinazolam plasma concentrations. Analysis of the relationship between percentage decrements in digit-symbol substitution and plasma N-desmethyladinazolam using the Hill equation revealed a EC50 of 325 ng/ml. These results establish the relationship between N-desmethyladinazolam plasma concentrations and performance effects; these data will be helpful in assessing the contribution of N-desmethyladinazolam to clinical effects observed after adinazolam administration.
Similar content being viewed by others
References
Amsterdam JD, Kaplan M, Potter L, Bloom L, Rickels K (1986) Adinazolam, a new triazolobenzodiazepine, and imipramine in the treatment of major depressive disorder. Psychopharmacology 88:484–488
Dunner D, Myers J, Khan A, Avery D, Ishiki D, Pyke R (1987) Adinazolam — a new antidepressant: findings of a placebo-controlled, double-blind study in outpatients with major depression. J Clin Psychopharmacol 7:170–172
Fleishaker C, Phillips JP (1989) Adinazolam pharmacokinetics and behavioral effects following administration of 20–60 mg oral doses of its mesylate salt in healthy volunteers. Psychopharmacology 99:34–39
Fleishaker JC, Phillips JP, Smith TC, Smith RB (1989a) Multiple dose pharmacokinetics and pharmacodynamics in elderly subjects. Pharmacol Res 6:379–386
Fleishaker JC, Phillips JP, Eller MG, Smith RB (1989b) Pharmacokinetics and pharmacodynamics of alprazolam following single and multiple oral doses of a sustained-release formulation. J Clin Pharmacol 29:543–549
Fleishaker JC, Friedman HL, Pollock SR, Smith TC (1990) Clinical pharmacology of adinazolam and N-desmethyladinazolam mesylate after single oral doses of each compound in healthy volunteers. Clin Pharmacol Ther 48:652–664
Ghoneim MM, Hinrichs JV, Mewaldt SP (1984) Dose-response analysis of the behavioral effects of diazepam: I. learning and memory. Psychopharmacology 82:291–295
Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Dekker, New York
Juhl RP (1988) Historical perspective on quantitative pharmacodynamics. In: Kroboth PD, Smith RB, Juhl RP (eds) Pharmacokinetics and pharmacodynamics. Volume 2. Current problems, potential solutions. Harvey Whitney, Cincinnati, pp 2–9
Kroboth PD, Smith RB, Erb RJ (1988) Tolerance to alprazolam after intravenous bolus and continuous infusion: psychomotor and EEG effects. Clin Pharmacol Ther 43:270–277
Lahti A, Sethy VH, Barsuhn C, Hester B (1983) Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine. Neuropharmacology 22:1277–1282
Peng GW (1982) Assay of adinazolam in plasma by liquid chromatography. J Pharm Sci 73:1173–1175
Pyke RE, Greenberg HS (1989) Double-blind comparison of alprazolam and adinazolam for panic and phobic disorders. J Clin Psychopharmacol 9:15–21
Randt CT, Brown ER (1983) Randt memory test administration manual. Life Science Associates, Bayport, New York
SAS Institute Inc. (1985) SAS user's guide: basics, version 5 edn. SAS Institute. Cary, North Carolina
Sethy VH, Harris DW (1982) Determination of the biological activity of alprazolam, triazolam, and their metabolites. Pharm Pharmacol 34:115–116
Sethy VH, Collins RJ, Daniels EG (1984) Determination of biological activity of adinazolam and its metabolites. J Pharm Pharmacol 36:546–548
Sethy VH, Francis JW, Day JS (1986) The effect of proadifen on the metabolism of adinazolam. J Pharm Pharmacol 38:631–632
Sheehan DV, Raj AB, Harnett-Sheehan K, Soto S, Lewis CP (1990) Adinazolam sustained release formulation in the treatment of generalized anxiety disorder. J Anxiety Disord 4:239–246
Smith RB, Kroboth PD (1987) Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects. Psychopharmacology 93:105–112
Smith RB, Kroboth PD, Vanderlugt JT, Phillips JP, Juhl RP (1984) Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology 84:452–456
Smith RB, Kroboth PD, Varner PD (1987) Pharmacodynamics of triazolam after intravenous administration. J Clin Pharmacol 27:971–979
Turmel A, DeMontigny C (1984) Sensitization of rat forebrain neurons to serotonin by adinazolam, an anti-depressant triazolobenzodiazepine. Eur J Pharmacol 99:241–244
Wechsler D (1955) A manual for the Wechsler adult intelligence scale. Psychological Corporation, New York
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fleishaker, J.C., Smith, T.C., Friedman, H. et al. N-desmethyladinazolam pharmacokinetics and behavioral effects following administration of 10–50 mg oral doses in healthy volunteers. Psychopharmacology 105, 181–185 (1991). https://doi.org/10.1007/BF02244306
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02244306